{"entity":{"id":"wtx-330","kind":"drug","name":"WTX-330","aka":[],"tldr":"WTX-330 is an experimental conditionally activated cytokine pro-drug from Werewolf Therapeutics, in phase 1 trials for advanced or metastatic solid tumours and non-Hodgkin lymphoma; its current status is not stated.","summary":"WTX-330 is a conditionally activated cytokine pro-drug (INDUKINE molecule) from Werewolf Therapeutics. A systemically delivered, conditionally activated interleukin-12 (IL-12) INDUKINE molecule that blocks IL-12 binding to its receptor in the circulation and normal tissue, extends half-life, and is activated by tumour-selective proteases. Its furthest stage is phase 1, for advanced or metastatic solid tumours and non-Hodgkin lymphoma. ClinicalTrials.gov registers it in 2 studies linked below. Same post-merger position as WTX-124 (S-4/A, 26 Oct 2026). Registry lists both WTX-330 trials (NCT05678998 phase 1; NCT06939283 phase 1b/2) as completed, while the company pipeline page still says 'We are currently enrolling patients in a Phase 1b/2 clinical trial'. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Werewolf Therapeutics: werewolftx.com","url":"https://werewolftx.com/our-pipeline/"},{"label":"Werewolf Therapeutics: werewolftx.com","url":"https://werewolftx.com/our-pipeline/"},{"label":"Werewolf Therapeutics: sec.gov","url":"https://www.sec.gov/Archives/edgar/data/1785530/000114036126040784/ny20081588x2_s4a.htm"},{"label":"ClinicalTrials.gov: trials of WTX-330","url":"https://clinicaltrials.gov/search?intr=WTX-330"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer","non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["werewolf-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05678998","nct06939283"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"WTX-330","modality":"Conditionally activated cytokine pro-drug (INDUKINE molecule)","mechanism":"A systemically delivered, conditionally activated interleukin-12 (IL-12) INDUKINE molecule that blocks IL-12 binding to its receptor in the circulation and normal tissue, extends half-life, and is activated by tumour-selective proteases.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/wtx-330/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"company":[{"id":"werewolf-therapeutics","kind":"company","name":"Werewolf Therapeutics","route":"/companies/werewolf-therapeutics/"}],"trial":[{"id":"nct06939283","kind":"trial","name":"A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma","route":"/trials/nct06939283/"},{"id":"nct05678998","kind":"trial","name":"WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma","route":"/trials/nct05678998/"}]}}